ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

JOURNALS

< Previous Issue   

Early View

(Articles online in advance of print)

Original Articles

Disease Site

Genitourinary Disease

Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence (p NA)
Paul L. Nguyen, Ming-Hui Chen, Clair J. Beard, W. Warren Suh, Toni K. Choueiri, Jason A. Efstathiou, Karen E. Hoffman, Marian Loffredo, Philip W. Kantoff, Anthony V. D'Amico
Published Online: Dec 2 2009 2:45PM
DOI: 10.1002/cncr.24818

After a postradiation therapy prostate-specific antigen (PSA) recurrence, men with moderate to severe comorbidity and those who are obese or older face a substantial risk of nonprostate-cancer-specific mortality. These men could be considered for enrollment to surveillance protocols with a plan to initiate salvage hormonotherapy if the PSA rises rapidly (eg, PSA doubling time <6 months) or the patient develops clinically or radiographically evident disease.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 180K)
Save Article

Editorial

Paired specimens : An opportunity to answer some important questions (p NA)
Naomi B Haas
Published Online: Dec 2 2009 2:45PM
DOI: 10.1002/cncr.24778

This editorial in response to Histologic Evaluation of Metastases in Renal Cell Carcinoma With Sarcomatoid Transformation and Its Implications for Systemic Therapy concludes that a molecular analysis of paired specimens is critical in determining whether sarcomatoid features will play a role in future therapy for this poor prognosis cancer.

See pages 000-000.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 67K)
Save Article

Original Articles

Discipline

Pediatric Oncology

Distinct features of colorectal cancer in children and adolescents : A population-based study of 159 cases (p NA)
Iyad Sultan, Carlos Rodriguez-Galindo, Hani El-Taani, Guido Pastore, Michela Casanova, Gianfranco Gallino, Andrea Ferrari
Published Online: Dec 2 2009 2:45PM
DOI: 10.1002/cncr.24777

Colorectal adenocarcinoma is extremely rare in children and adolescents. Distinct clinical features contribute to worse outcome. In the current study, the records of children and adolescents were compared with those of adults.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 462K)
Save Article

Disease Site

Genitourinary Disease

Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder (p NA)
Peter U. Ardelt, Burkhard Kneitz, Patrick Adam, Cora Reiss, Arkadius Kocot, Joachim Fensterle, Limor Chen, Renata Pasqualini, Wadih Arap, Elmar W. Gerharz, Hubertus Riedmiller
Published Online: Dec 2 2009 2:45PM
DOI: 10.1002/cncr.24770

The finding that successful bacillus Calmette-Guerin (BCG) immunotherapy for superficial transitional cell carcinoma of the bladder was unpredictable resulted in delayed alternative treatment. The authors now report a serologic prediction marker for the outcome of BCG immunotherapy. Investigation of a patient's humoral immune response allows monitoring and, thus, individual design of the immunotherapy.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 410K)
Save Article

Lung Disease

Underutilization of radiotherapy for lung cancer in New South Wales, Australia (p NA)
Shalini K. Vinod, Leonardo Simonella, David Goldsbury, Geoff P. Delaney, Bruce Armstrong, Dianne L. O'Connell
Published Online: Dec 2 2009 2:46PM
DOI: 10.1002/cncr.24762

There is underutilization of radiotherapy for lung cancer in New South Wales, Australia, especially in small cell lung cancer. The use of combined-modality treatment for potentially curable lung cancers is suboptimal.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 166K)
Save Article

Discipline

Pediatric Oncology

Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol (p NA)
Johannes E.A. Wolff, Pablo Hernaiz Driever, Bernhard Erdlenbruch, Rolf D. Kortmann, Stefan Rutkowski, Torsten Pietsch, Crystal Parker, Monica Warmuth Metz, Astrid Gnekow, Christof M. Kramm
Published Online: Dec 2 2009 2:46PM
DOI: 10.1002/cncr.24730

Comparing 97 pediatric patients with histologically defined high-grade glioma and radiologically defined diffuse intrinsic pontine glioma to previous protocols, we found that chemotherapy with cisplatin, ifosfamide, etoposide, and vincristine in combination given simultaneous with radiation and as maintenance treatment after radiation followed by maintenance treatment with valproic acid improved the survival only of those patients who had gross total resection.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 188K)
Save Article

Disease Site

Hematologic Malignancies

Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody : The M. D. Anderson Cancer Center experience of 349 patients (p NA)
Nikolay D. Dimov, L. Jeffrey Medeiros, Hagop M. Kantarjian, Jorge E. Cortes, Kun-Sang Chang, Carlos E. Bueso-Ramos, Farhad Ravandi
Published Online: Nov 30 2009 12:31PM
DOI: 10.1002/cncr.24775

Promyelocytic leukemia immunofluorescence staining is a rapid (<4 hours turnaround time), reliable, sensitive (98.9%), and specific (98.7%) frontline diagnostic approach that can facilitate initiation of targeted therapy, particularly in clinical settings where cytogenetic and molecular testing are not readily available.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 192K)
Save Article

Discipline

Racial Disparities

Variations in gastric cancer care : A trend beyond racial disparities (p NA)
Waddah B. Al-Refaie, Greer Gay, Beth A. Virnig, Jennifer F. Tseng, Andrew Stewart, Selwyn M. Vickers, Todd. M. Tuttle, Barry W. Feig
Published Online: Nov 30 2009 12:31PM
DOI: 10.1002/cncr.24772

This United States multihospital study demonstrated that there were significant variations in treatment for gastric cancer among ethnic groups. It is noteworthy that gastric cancer treatment overall deviated from current recommended guidelines beyond racial disparities to a wider national problem.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 151K)
Save Article

Correspondence

Reply to Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation (p NA)
Gary M. Freedman
Published Online: Nov 30 2009 12:31PM
DOI: 10.1002/cncr.24829

Abstract  |  References | Full Text:   HTML,   PDF (Size: 50K)
Save Article

Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation (p NA)
Fabio Puglisi
Published Online: Nov 30 2009 12:31PM
DOI: 10.1002/cncr.24826

Abstract  |  References | Full Text:   HTML,   PDF (Size: 49K)
Save Article

Original Articles

Disease Site

Hepatobiliary Disease

Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma (p NA)
Masayuki Nagahashi, Yoshio Shirai, Toshifumi Wakai, Jun Sakata, Yoichi Ajioka, Tatsuya Nomura, Yoshiaki Tsuchiya, Katsuyoshi Hatakeyama
Published Online: Nov 30 2009 12:32PM
DOI: 10.1002/cncr.24766

For pathologic T1 extrahepatic cholangiocarcinoma, the long-term outcomes postresection were significantly better for patients with mucosal tumors than for patients with tumors that have invaded (but not penetrated) the fibromuscular layer. This suggests that the depth of tumor invasion affects the postresection prognosis for patients with pathologic T1 extrahepatic cholangiocarcinoma.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 301K)
Save Article

Gastrointestinal Disease

Extracapsular lymph node spread : A new prognostic factor in gastric cancer (p NA)
Hakan Alakus, Arnulf H. Hölscher, Guido Grass, Eva Hartmann, Christian Schulte, Uta Drebber, Stephan E. Baldus, Elfriede Bollschweiler, Ralf Metzger, Stefan P. Mönig
Published Online: Nov 30 2009 12:32PM
DOI: 10.1002/cncr.24764

The present study demonstrated that infiltration of cancer cells beyond the capsule of the metastatic lymph nodes is of high prognostic value in gastric cancer, giving additional information to the International Union Against Cancer pN category and being helpful in the identification of gastric cancer patients with inferior prognosis. In future staging systems, the presence of extracapsular lymph node involvement should be considered for gastric cancer.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 234K)
Save Article

Discipline

Radiation Oncology

Stage I nonsmall cell lung cancer in patients aged ge75 years : Outcomes after stereotactic radiotherapy (p NA)
Cornelis J. A. Haasbeek, Frank J. Lagerwaard, Marilisa E. Antonisse, Ben J. Slotman, Suresh Senan
Published Online: Nov 30 2009 12:32PM
DOI: 10.1002/cncr.24759

Surgical resection of stage I lung cancer in elderly patients was associated with increased morbidity and mortality. Good local control with minimal toxicity was observed after stereotactic radiotherapy in these patients.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 224K)
Save Article

Disparities Research

A black-white comparison of the quality of stage-specific colon cancer treatment (p NA)
Jamillah Berry, Lee Caplan, Sharon Davis, Patrick Minor, Margaret Counts-Spriggs, Roni Glover, Vickie Ogunlade, Kevin Bumpers, John Kauh, Otis W. Brawley, Christopher Flowers
Published Online: Nov 30 2009 12:32PM
DOI: 10.1002/cncr.24757

The sociodemographic characteristics and stage-specific quality of care (effectiveness and timeliness) of blacks were similar to those of whites in a retrospective study of billing, medical, and cancer registry records of 365 university hospital patients (175 blacks and 190 whites) diagnosed with stage II-IV colon cancer between 2000 and 2005. There were no significant racial differences in mortality, although age, diagnostic stage, and health insurance coverage were independently associated.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 147K)
Save Article

Pediatric Oncology

Aggressive fibromatosis in children and adolescents : The Italian experience (p NA)
Cristina Meazza, Gianni Bisogno, Alessandro Gronchi, Marco Fiore, Giovanni Cecchetto, Rita Alaggio, Giuseppe M. Milano, Michela Casanova, Modesto Carli, Andrea Ferrari
Published Online: Nov 30 2009 12:32PM
DOI: 10.1002/cncr.24679

The authors retrospectively analyzed a series of 94 children and adolescents with aggressive fibromatosis (AF). The results suggested that these tumors may have much the same natural history as AF adults. Interesting responses to systemic treatments were observed, particularly to low-dose chemotherapy.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 129K)
Save Article

Disease Site

Genitourinary Disease

A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer (p NA)
Bryan J. Donnelly, John C. Saliken, Penelope M. A. Brasher, Scott D. Ernst, John C. Rewcastle, Harold Lau, John Robinson, Kiril Trpkov
Published Online: Nov 24 2009 9:30AM
DOI: 10.1002/cncr.24779

Disease progression was similar in both arms initially, but with longer follow-up, the trend favored cryoablation. There were significantly fewer positive post-treatment biopsies in the cryoablation arm.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 228K)
Save Article

Head and Neck Disease

Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States (p NA)
Asal N. Shoushtari, Nina P. Rahimi, David J. Schlesinger, Paul W. Read
Published Online: Nov 24 2009 9:30AM
DOI: 10.1002/cncr.24752

According to a nationwide survey, approximately 40.4% of radiation oncology practices in the United States screen for human papillomavirus (HPV) DNA or p16 in oropharyngeal carcinomas, whereas only 12.4% of those use it to further direct care. Clinical trials to further elucidate how HPV or p16 DNA status should direct care in oropharyngeal carcinoma are warranted.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 154K)
Save Article

Erratum

Erratum (p NA)

Published Online: Nov 20 2009 3:18PM
DOI: 10.1002/cncr.24825

Abstract | Full Text:   HTML,   PDF (Size: 37K)
Save Article

Original Articles

Discipline

Epidemiology

The impact of health insurance status on the survival of patients with head and neck cancer (p NA)
Joseph Kwok, Scott M. Langevin, Athanassios Argiris, Jennifer R. Grandis, William E. Gooding, Emanuela Taioli
Published Online: Nov 20 2009 3:18PM
DOI: 10.1002/cncr.24774

Health insurance status is an independent predictor of head and neck cancer survival.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 213K)
Save Article

Disease Site

Neuro-Oncology

Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer (p NA)
Kan Yonemori, Koji Tsuta, Makiko Ono, Chikako Shimizu, Akihiro Hirakawa, Tadashi Hasegawa, Yutaka Hatanaka, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara
Published Online: Nov 20 2009 3:18PM
DOI: 10.1002/cncr.24735

Brain metastases of triple-negative or basal-type breast cancers often may disrupt the blood brain barrier, whereas brain metastases of HER2/neu-positive breast cancer tend to preserve the blood brain barrier.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 263K)
Save Article

Original Article

Disease Site

Gynecologic Oncology

Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer : A Gynecologic Oncology Group Study (p NA)
John H. Farley, Chunqiao Tian, G. Scott Rose, Carol L. Brown, Michael Birrer, John I. Risinger, J. Tate Thigpen, Gini F. Fleming, Holly H. Gallion, G. Larry Maxwell
Published Online: Nov 18 2009 12:06PM
DOI: 10.1002/cncr.24769

Black patients with advanced stage or recurrent endometrial cancer, treated on 4 Gynecologic Oncology Group (GOG) protocols, had similar dose intensity and severe chemotherapy-related toxicity compared with white patients. This suggests that previously described racial disparities in survival among patients in GOG trials may have a novel etiology.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 150K)
Save Article

Original Articles

Disease Site

Hematologic Malignancies

Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma (p NA)
Eric W. Schaefer, Shaji Kumar, Angela Dispenzieri, Jacob B. Allred, Morie A. Gertz, Martha Q. Lacy, S. Vincent Rajkumar, Sumithra J. Mandrekar
Published Online: Nov 18 2009 12:10PM
DOI: 10.1002/cncr.24767

In the current era of immunomodulatory agents in multiple myeloma, response criteria determined solely by the baseline and the best level of reduction in the tumor estimate, with little emphasis given to the trend in reduction of the tumor marker, may no longer be adequate. The treatment-based trend metric of average reduction in the percentage of serial serum monoclonal protein measurements remaining relative to baseline, as proposed in this work, demonstrated better predictive ability than response-based metrics for progression-free survival.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 162K)
Save Article

Commentary

Addressing cancer health disparities using a global biopsychosocial approach (p NA)
Denae King, Patricia Miranda, Beverly Gor, Robin Fuchs-Young, Janice Chilton, Richard Hajek, Isabel Torres-Vigil, Mariá A. Hernández-Valero, S. Amy Snipes, Lovell Jones
Published Online: Nov 18 2009 12:10PM
DOI: 10.1002/cncr.24765

The Center for Research on Minority Health has translated the biopsychosocial framework to address global cancer health disparities through the integration of biological and behavioral determinants, along with community-based research and educational approaches. In this article, the authors illustrate how to implement the biopsychosocial approach to more comprehensively and effectively address cancer health disparities.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 102K)
Save Article

Original Articles

Disease Site

Genitourinary Disease

Urinary diversion and morbidity after radical cystectomy for bladder cancer (p NA)
John L. Gore, Hua-Yin Yu, Claude Setodji, Jan M. Hanley, Mark S. Litwin, Christopher S. Saigal, the Urologic Diseases in America Project
Published Online: Nov 18 2009 3:24PM
DOI: 10.1002/cncr.24763

The rate of continent urinary diversion after radical cystectomy for bladder cancer varies by patient and provider characteristics. In the current study, among patients undergoing radical cystectomy for muscle-invasive bladder cancer, postoperative morbidity and mortality outcomes did not vary by diversion type.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 144K)
Save Article

Head and Neck Disease

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer : A Trial of the NCIC Clinical Trials Group (p NA)
Scott A. Laurie, Lillian L. Siu, Eric Winquist, Andrew Maksymiuk, Erica L. Harnett, Wendy Walsh, Dongsheng Tu, Wendy R. Parulekar
Published Online: Nov 18 2009 12:11PM
DOI: 10.1002/cncr.24745

In patients with advanced salivary gland cancers, platinum-gemcitabine combination chemotherapy was found to have modest activity but was insufficient to warrant further study. Enrollment of patients with these rare cancers onto well-designed clinical trials remains an urgent priority.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 159K)
Save Article

Original articles

Disease Site

Hematologic Malignancies

Expression of interleukin 15 in primary adult acute lymphoblastic leukemia (p NA)
Shuling Wu, Lars Fischer, Nicola Gökbuget, Stefan Schwartz, Thomas Burmeister, Michael Notter, Dieter Hoelzer, Hendrik Fuchs, Igor Wolfgang Blau, Wolf K Hofmann, Eckhard Thiel
Published Online: Nov 18 2009 12:10PM
DOI: 10.1002/cncr.24729

High expression of IL-15 correlates with disease recurrence of adult B-lineage acute lymphoblastic leukemia.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 184K)
Save Article

Original Articles

Discipline

Symptom Control and Palliative Care

A multidimensional examination of correlates of fatigue during radiotherapy (p NA)
Amanda Purcell, Jennifer Fleming, Sally Bennett, Kathleen McGuane, Bryan Burmeister, Terry Haines
Published Online: Nov 17 2009 11:52AM
DOI: 10.1002/cncr.24731

Fatigue is comprised of multiple dimensions. The objective of the current study was to investigate cancer-related fatigue in a radiotherapy sample using a multidimensional conceptualization to determine whether correlates of fatigue are consistent across all dimensions or whether each fatigue dimension has its own unique pattern of correlates.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 170K)
Save Article

Disease Site

Genitourinary Disease

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients : Implications for clinical trial design and interpretation (p NA)
Sujata Patil, Nicole Ishill, John Deluca, Robert J. Motzer
Published Online: Nov 17 2009 11:53AM
DOI: 10.1002/cncr.24713

The risk-group distribution for metastatic renal cell carcinoma (RCC) patients in the clinical trial population at Memorial Sloan-Kettering Cancer Center has shifted from 1975 to 2007. These shifts have direct implications for data analysis, interpretation of metastatic RCC trends, and drug development.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 230K)
Save Article

Editorials

We need better randomized comparison trials of prostate cancer (p NA)
W. Robert Lee
Published Online: Nov 18 2009 12:13PM
DOI: 10.1002/cncr.24780

More than 50 years after the first randomized oncology trial, the number of randomized trials comparing differing primary treatments for prostate cancer is disappointing. One of these rare, randomized primary treatment comparisons appears in this edition of Cancer, and the investigators are to be congratulated for their efforts comparing cryotherapy with external beam radiotherapy.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 64K)
Save Article

Original Articles

Discipline

Clinical Trials

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients : United States Military Cancer Institute Clinical Trials Group Study I-04 (p NA)
Mark G. Carmichael, Linda C. Benavides, Jarrod P. Holmes, Jeremy D. Gates, Elizabeth A. Mittendorf, Sathibalan Ponniah, George E. Peoples
Published Online: Nov 18 2009 12:12PM
DOI: 10.1002/cncr.24756

This article describes the results of the first phase 1 trial of the HER-2/neu peptide (GP2) vaccine in breast cancer patients. Results show that the vaccine appears safe and well tolerated, with minimal local/systemic toxicity, and that it elicits HER-2-neu-specific immune responses.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 466K)
Save Article

Disease Site

Sarcoma

Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign (p NA)
Matthias R. Benz, Johannes Czernin, Sarah M. Dry, William D. Tap, Martin S. Allen-Auerbach, David Elashoff, Michael E. Phelps, Wolfgang A. Weber, Fritz C. Eilber
Published Online: Nov 18 2009 12:11PM
DOI: 10.1002/cncr.24755

Quantitative F18-fluorodeoxyglucose positron emission tomography imaging distinguished between malignant peripheral nerve sheath tumors and neurofibromas with high accuracy. In contrast, malignant peripheral nerve sheath tumors and schwannomas were less reliably distinguished.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 302K)
Save Article

Discipline

Symptom Control and Palliative Care

Methadone initiation and rotation in the outpatient setting for patients with cancer pain (p NA)
Henrique A. Parsons, Maxine de la Cruz, Badi El Osta, Zhijun Li, Bianca Calderon, J. Lynn Palmer, Eduardo Bruera
Published Online: Nov 18 2009 12:13PM
DOI: 10.1002/cncr.24754

Outpatient methadone initiation and rotation for cancer pain treatment showed very high success rates (92% and 84%, respectively). The use of methadone was associated with decreased frequency of opioid toxicities.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 209K)
Save Article

Disease Site

Sarcoma

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) (p NA)
Julia Haeusler, Andreas Ranft, Tobias Boelling, Georg Gosheger, Gabriele Braun-Munzinger, Volker Vieth, Stefan Burdach, Henk van den Berg, Heribert Juergens, Uta Dirksen
Published Online: Nov 18 2009 12:12PM
DOI: 10.1002/cncr.24740

Our data on the value of local treatment in patients with primary, extrapulmonary, metastatic Ewing sarcoma suggest that local treatment of involved sites improves the prognosis and should complement systemic treatment whenever possible.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 174K)
Save Article

Melanoma

Isolated limb infusion with cytotoxic agents: A simplified approach for venous access (p NA)
Ajit Vyas, Rony Avritscher, Joe Ensor, Merrick Ross, Michael J. Wallace
Published Online: Nov 18 2009 12:13PM
DOI: 10.1002/cncr.24736

As evinced by the significantly lower fluoroscopy time needed for combined arterial and venous catheter placement for isolated limb infusion using a novel modified technique, our results demonstrate that the ipsilateral venous access approach is technically easier than the conventional contralateral venous approach.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 303K)
Save Article

Hematologic Malignancies

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion (p NA)
Kimmo Porkka, H. Jean Khoury, Ronald L. Paquette, Yousif Matloub, Ritwik Sinha, Jorge E. Cortes
Published Online: Nov 18 2009 12:12PM
DOI: 10.1002/cncr.24734

In patients with chronic myeloid leukemia in chronic phase, dasatinib 100 mg once daily significantly minimized the occurrence of pleural effusion. Dasatinib short-term and long-term efficacy was similar in patients with or without pleural effusion.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 265K)
Save Article

Discipline

Symptom Control and Palliative Care

Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer (p NA)
Maxine de la Cruz, David Hui, Henrique A. Parsons, Eduardo Bruera
Published Online: Nov 13 2009 3:20PM
DOI: 10.1002/cncr.24751

In the current study, placebo and nocebo effects occurred frequently in advanced cancer patients with fatigue (56% and 71%, respectively). These results should be considered in designing future fatigue trials.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 197K)
Save Article

Clinical Trials

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases (p NA)
Eitan Amir, Christine E. Simmons, Orit C. Freedman, George Dranitsaris, David E. C. Cole, Reinhold Vieth, Wei S. Ooi, Mark Clemons
Published Online: Nov 13 2009 3:20PM
DOI: 10.1002/cncr.24749

High-dose vitamin D is safe in patients without comorbid conditions causing hypersensitivity to vitamin D. However, when given to patients with metastatic breast cancer to bone, it did not reduce bone resorption markers, nor was it associated with a significant palliative benefit.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 204K)
Save Article

Disease Site

Breast Disease

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors (p NA)
H. Irene Su, Mary D. Sammel, Jamie Green, Luke Velders, Corrie Stankiewicz, Jennifer Matro, Ellen W. Freeman, Clarisa R. Gracia, Angela DeMichele
Published Online: Nov 13 2009 3:20PM
DOI: 10.1002/cncr.24746

Antimullerian hormone and inhibin B are 2 additional measures of postchemotherapy ovarian function in late reproductive-aged breast cancer survivors. These hormones may supplement limited current tools for assessing and predicting postchemotherapy ovarian function.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 143K)
Save Article

Melanoma

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508 (p NA)
Joseph I. Clark, James Moon, Laura F. Hutchins, Jeffrey A. Sosman, W. Martin Kast, Diane M. Da Silva, P. Y. Liu, John A. Thompson, Lawrence E. Flaherty, Vernon K. Sondak
Published Online: Nov 13 2009 3:20PM
DOI: 10.1002/cncr.24739

This combination of thalidomide and temozolomide does not appear to have a clinical benefit that exceeds dacarbazine alone. We would not recommend it further for phase 3 trials or for standard community use.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 144K)
Save Article

Discipline

Clinical Trials

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy (p NA)
Samuel Bral, Michaël Duchateau, Harijati Versmessen, Douwe Verdries, Benedikt Engels, Mark De Ridder, Koen Tournel, Christine Collen, Hendrik Everaert, Denis Schallier, Jacques De Greve, Guy Storme
Published Online: Nov 13 2009 3:32PM
DOI: 10.1002/cncr.24732

In this phase 1/2 trial, the authors assessed the possibility of radiation dose escalation using helical tomotherapy in a concurrent approach for unselected patients with inoperable, locally advanced nonsmall cell lung cancer. The maximum tolerated dose was set at 67.2 grays, and cisplatin/docetaxel was given weekly, resulting in an acceptable acute and late toxicity profile with a 61% response rate.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 222K)
Save Article

Disease Site

Melanoma

Characteristics associated with early and late melanoma metastases (p NA)
Jeremy A. Brauer, Cooper C. Wriston, Andrea B. Troxel, Rosalie Elenitsas, Daniel B. Shin, DuPont Guerry, Michael E. Ming
Published Online: Nov 13 2009 3:32PM
DOI: 10.1002/cncr.24724

The authors performed a nested case-control study comparing 549 patients who had melanoma and developed metastases, including 320 patients who developed metastasis within 3 years after undergoing definitive surgery (early metastasis [EM]) and 70 patients who developed metastasis 8 years after undergoing definitive surgery (late metastasis [LM]), with 549 patients who had melanoma and did not develop metastasis. Two previously undescribed risk factors for metastases at any time interval were identified: a personal history of nonmelanoma skin cancer (P = .006) and a history of cancer other than skin cancer (P = .020). The results indicated that, compared with LM patients, EM patients were more likely to have thicker lesions (P < .001), ulcerated lesions (P = .016), and a history of nonmelanoma skin cancer (P = .024).

Abstract  |  References | Full Text:   HTML,   PDF (Size: 153K)
Save Article

Lung Disease

Modeling excess lung cancer risk among screened arm participants in the Mayo Lung Project (p NA)
Deborah L. Goldwasser, Marek Kimmel
Published Online: Nov 13 2009 3:32PM
DOI: 10.1002/cncr.24722

The authors fit a modified 2-stage clonal expansion (TSCE) model of excess lung cancer risk to long-term follow-up data from the Mayo Lung Project. The excess lung cancer risk observed among screening arm participants was found to be statistically significant with respect to the TSCE model framework, in part because of the incorporation of key risk correlates of age and screen frequency into the estimation framework.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 186K)
Save Article

Discipline

Translational Research

Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer (p NA)
Teruo Inamoto, Bogdan A. Czerniak, Colin P. Dinney, Ashish M. Kamat
Published Online: Nov 11 2009 10:36AM
DOI: 10.1002/cncr.24737

A significant number of deaths from bladder cancer result from inability to predict which patients will have disease recurrence despite seemingly good response to therapy as well as lack of effective salvage therapies in those who do not respond to conventional agents. In this study, the authors demonstrated that the cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 was positively associated with tumor recurrence and poor prognosis in patients with bladder cancer.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 283K)
Save Article

Pediatric Oncology

Health status of the oldest adult survivors of cancer during childhood (p NA)
Lisa B Kenney, Cheryl Medeiros Nancarrow, Julie Najita, Lynda M. Vrooman, Monica Rothwell, Christopher Recklitis, Frederick P. Li, Lisa Diller
Published Online: Nov 11 2009 10:36AM
DOI: 10.1002/cncr.24718

Adult survivors of childhood cancer aged >50 years report a higher prevalence of cardiovascular disease, physical impairments, and fatigue compared with their age-matched relatives, and they remain at risk for treatment-associated premature mortality 40 years after their initial therapy.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 148K)
Save Article

Original Article

Disease Site

Endocrine Disease

Treatment patterns of aging Americans with differentiated thyroid cancer (p NA)
Henry S. Park, Sanziana A. Roman, Julie Ann Sosa
Published Online: Nov 11 2009 10:36AM
DOI: 10.1002/cncr.24717

Using the Surveillance, Epidemiology, and End Results database, the authors demonstrated that elderly patients with differentiated thyroid cancer received less aggressive surgical and radioactive iodine (RAI) treatment than younger patients despite having more advanced disease. The results also demonstrated that both surgical and RAI treatment are associated with improved survival among elderly patients.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 242K)
Save Article

Original Articles

Disease Site

Neuro-Oncology

The role of postoperative radiotherapy for the treatment of gangliogliomas (p NA)
Dirk Rades, Lena Zwick, Jan Leppert, Matteo M Bonsanto, Volker Tronnier, Juergen Dunst, Steven E. Schild
Published Online: Nov 11 2009 10:36AM
DOI: 10.1002/cncr.24716

This study investigated the potential benefit of postoperative radiotherapy for local control (LC) and overall survival (OS) in a series of 402 patients with ganglioglioma. In both low-grade and high-grade tumors, irradiation significantly improved LC but not OS after subtotal resection and should be considered for these patients; whereas, after gross total resection, irradiation did not significantly improve LC or OS and, thus, did not appear to be required.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 331K)
Save Article

Hepatobiliary Disease

Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma : A retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma (p NA)
Shozo Iwamoto, Taizo Yamaguchi, Osamu Hongo, Hideki Iwamoto, Hayato Sanefuji
Published Online: Nov 11 2009 10:35AM
DOI: 10.1002/cncr.24678

The authors report their successful results using angiographic subsegmentectomy (AS) for the treatment of hepatocellular carcinoma (HCC). The treatment involved the simultaneous embolization of the peripheral feeding artery and the portal vein, and almost all of the HCC and the peripheral liver parenchyma developed complete anatomic necrosis. The authors concluded that AS should be the first-line treatment for patients with stage I and II HCC.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 387K)
Save Article

Lung Disease

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer (p NA)
Dae Ho Lee, Sang-We Kim, Cheolwon Suh, Jung-Shin Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Im-Il Na, Jae Cheol Lee, Baek-Yeol Ryoo, Sung Hyun Yang
Published Online: Nov 10 2009 3:53PM
DOI: 10.1002/cncr.24719

Belotecan, a new camptothecin analogue, when combined with cisplatin, demonstrated promising antitumor activity and a manageable toxicity profile in chemotherapy-naive patients with extensive-stage small cell lung cancer.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 136K)
Save Article

Gastrointestinal Disease

Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin : A single-institution experience (p NA)
Jamie F. Shapiro, Judy L. Chase, Robert A. Wolff, Laura A. Lambert, Paul F. Mansfield, Michael J. Overman, Aki Ohinata, Jun Liu, Xuemei Wang, Cathy Eng
Published Online: Nov 10 2009 3:53PM
DOI: 10.1002/cncr.24715

Systemic chemotherapy may have a role for patients with surgically unresectable appendiceal neoplasms. Further trials using systemic chemotherapy are warranted in patients who are suboptimal surgical candidates with appendiceal neoplasms.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 130K)
Save Article

Discipline

Symptom Control and Palliative Care

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy (p NA)
Yu Xuan Koo, Daniel S. W. Tan, Iain B. Tan, Miriam Tao, Wan Cheng Chow, Soon Thye Lim
Published Online: Nov 6 2009 3:37PM
DOI: 10.1002/cncr.24742

All lymphoma patients in hepatitis B virus (HBV) endemic regions should be tested for HBV core antibody in addition to hepatitis B surface antigen. Low rate of HBV reactivation does not support the routine use of antiviral prophylaxis in patients with past HBV infection.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 143K)
Save Article

Correspondence

Reply to The atypical Spitz tumor of uncertain biologic potential : A series of 67 patients from a single institution (p NA)
Mathew W. Ludgate, Douglas R. Fullen, Lori Lowe, Timothy Johnson
Published Online: Nov 6 2009 3:37PM
DOI: 10.1002/cncr.24694

Abstract  |  References | Full Text:   HTML,   PDF (Size: 56K)
Save Article

Original Articles

Disease Site

Neuro-Oncology

Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes (p NA)
Arabinda Das, Naren L. Banik, Swapan K. Ray
Published Online: Nov 5 2009 2:16PM
DOI: 10.1002/cncr.24699

Glioblastoma remains incurable with conventional chemotherapeutic agents. Plant-derived flavonoids induced apoptotic death in human glioblastoma T98G (mutant p53) and U87MG (wild-type p53) cells via activation of multiple mechanisms without affecting human normal astrocytes.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 1406K)
Save Article

Gastrointestinal Disease

Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer (p NA)
Caiping Gao, Zhiyu Zhang, Wenzhong Liu, Shudong Xiao, Weiqi Gu, Hong Lu
Published Online: Nov 4 2009 12:02PM
DOI: 10.1002/cncr.24743

Helicobacter pylori infection resulted in decreased microRNA-218 (miR-218) expression. In the current study, reduced miR-218 expression was associated with high nuclear factor B activation in gastric cancer.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 305K)
Save Article

Endocrine Disease

Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer (p NA)
Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller-Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat Müller
Published Online: Nov 4 2009 12:02PM
DOI: 10.1002/cncr.24738

The results of the current study demonstrate an independent predictive value of the calcitonin precursor procalcitonin in medullary thyroid cancer. The procalcitonin:calcitonin ratio might represent a novel and easily accessible tool leading to more personalized diagnostic and therapeutic strategies for patients with medullary thyroid cancer.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 357K)
Save Article

Discipline

Clinical Trials

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma : Results from a Multicenter Study (p NA)
Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen Ganjoo, Michael E. Williams, Myron S. Czuczman, K. Sue Robinson, Robin Joyce, Richard H. van der Jagt, Bruce D. Cheson
Published Online: Nov 4 2009 12:01PM
DOI: 10.1002/cncr.24714

Single-agent bendamustine demonstrated encouraging efficacy and manageable toxicity in rituximab-refractory and chemotherapy-refractory patients with non-Hodgkin lymphoma.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 182K)
Save Article

Disease Site

Hepatobiliary Disease

An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate (p NA)
Daniel Keizman, Natalie Maimon, Maya Ish-Shalom, Dana Buchbut, Moshe Inbar, Baruch Klein, Joelle Bernheim, Ilana Goldiner, Alicia Leikin-Frenkel, Fred Konikoff
Published Online: Nov 4 2009 12:01PM
DOI: 10.1002/cncr.24710

The current study indicates that C57BL/6 receiving weekly intraperitoneal injections of oxaliplatin at a dose of 6 mg/kg up to a total dose of 24 mg/kg could be used as a model for chemotherapy-associated steatohepatitis (CASH). Oral fatty acid bile acid conjugate therapy reduced the development of CASH in animals that were treated with oxaliplatin.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 133K)
Save Article

Breast Disease

Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk (p NA)
William D. Dupont, Joan P. Breyer, Kevin M. Bradley, Peggy A. Schuyler, W. Dale Plummer, Melinda E. Sanders, David L. Page, Jeffrey R. Smith
Published Online: Nov 4 2009 12:01PM
DOI: 10.1002/cncr.24702

Protein phosphatase 2A (PP2A) is a major cellular phosphatase and plays key regulatory roles in growth, differentiation, and apoptosis. In this study, the authors identified significant risk and protective haplotypes of the PP2A structural regulatory subunit A isoform (PPP2R1A). Women who had both the PPP2R1A risk haplotype and a history of proliferative breast disease had a further elevation in breast cancer risk.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 678K)
Save Article

Editorials

Where does the combination of sorafenib and interferon in renal cell carcinoma stand? (p NA)
Keith T. Flaherty
Published Online: Nov 4 2009 12:00PM
DOI: 10.1002/cncr.24688

Sorafenib can be combined safely with interferon, but the results of a recent randomized, phase 2 trial cast doubt on the value of further evaluating this combination. The renal cell carcinoma field continues to wrestle with the value of combining targeted therapies with cytokines.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 72K)
Save Article

Original Articles

Discipline

Pediatric Oncology

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia (p NA)
Hiroto Inaba, Clinton F. Stewart, Kristine R. Crews, Shengping Yang, Stanley Pounds, Ching-Hon Pui, Jeffrey E. Rubnitz, Bassem I. Razzouk, Raul C. Ribeiro
Published Online: Nov 2 2009 11:46AM
DOI: 10.1002/cncr.24712

The authors evaluated the maximum tolerated dose and dose-limiting toxicities of a 5-day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory acute myeloid leukemia. This regimen offers a treatment alternative for patients, especially those who have received anthracycline-containing chemotherapy.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 159K)
Save Article

Disease Site

Gastrointestinal Disease

Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma (p NA)
Robert R. McWilliams, Gloria M. Petersen, Kari G. Rabe, Leonard M. Holtegaard, Pamela J. Lynch, Michele D. Bishop, W. Edward Highsmith Jr
Published Online: Nov 2 2009 11:46AM
DOI: 10.1002/cncr.24697

In a case-control study, the authors comprehensively tested for 39 known CFTR mutations in 949 patients and 13,340 controls. They found an increased risk of pancreatic adenocarcinoma associated with CFTR carrier status (odds ratio [OR], 1.40; P = .027) that was even more marked among patients who were younger at diagnosis (OR, 1.82; P = .01).

Abstract  |  References | Full Text:   HTML,   PDF (Size: 143K)
Save Article

Sarcoma

Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate (p NA)
Jonathan C. Trent, Shalin S. Patel, Jianhu Zhang, Dejka M. Araujo, Juan-Carlos Plana, Daniel J. Lenihan, Dominic Fan, Shreyaskumar R. Patel, Robert S. Benjamin, Aarif Y. Khakoo
Published Online: Nov 2 2009 11:47AM
DOI: 10.1002/cncr.24683

Cardiotoxicity caused by imatinib mesylate in gastrointestinal stromal tumor and other sarcoma patients is uncommon and manageable, and should not be a reason to withhold imatinib mesylate therapy from cancer patients who would derive benefit. However, the long-term effects of imatinib mesylate on cardiac function remain unknown, and in vitro and in vivo studies support the notion that imatinib mesylate remains a potential cardiotoxin.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 255K)
Save Article

Genitourinary Disease

Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer (p NA)
Shahana Majid, Altaf A. Dar, Varahram Shahryari, Hiroshi Hirata, Ardalan Ahmad, Sharanjot Saini, Yuichiro Tanaka, Angela V. Dahiya, Rajvir Dahiya
Published Online: Nov 2 2009 3:53PM
DOI: 10.1002/cncr.24662

Epigenetic silencing of tumor suppressor gene B-cell translocation gene 3 in prostate cancer can be reactivated by genistein induced promoter demethylation and active histone modification. Genistein being a natural, nontoxic, dietary isoflavone may be a novel, advantageous, therapeutic agent for treating prostate cancer.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 860K)
Save Article

Correspondence

Preoperative assessment enables the early detection and successful treatment of lymphedema (p NA)
Sandi Hayes, Bruce Cornish, Beth Newman
Published Online: Oct 28 2009 5:05PM
DOI: 10.1002/cncr.24733

Abstract  |  References | Full Text:   HTML,   PDF (Size: 53K)
Save Article

Original Articles

Disease Site

Melanoma

A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma (p NA)
Evan M. Hersh, Steven J. O'Day, Antoni Ribas, Wolfram E. Samlowski, Michael S. Gordon, Deganit E. Shechter, Alicia A. Clawson, Rene Gonzalez
Published Online: Oct 28 2009 5:05PM
DOI: 10.1002/cncr.24720

Treatment with nab-paclitaxel is active in both chemotherapy-naive and previously treated patients with metastatic malignant melanoma. Survival (pending confirmation in a randomized clinical trial) appeared to be longer than that reported in the literature for such patients.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 232K)
Save Article

Discipline

Cancer Disparities

Racial differences in treatment and outcomes among patients with early stage bladder cancer (p NA)
Brent K. Hollenbeck, Rodney L. Dunn, Zaojun Ye, John M. Hollingsworth, Cheryl T. Lee, John D. Birkmeyer
Published Online: Oct 28 2009 5:05PM
DOI: 10.1002/cncr.24701

Black patients with early stage (ie, superficial) bladder cancer fared worse in terms of overall survival compared with white patients. However, this disparity was not attributable to the intensity of the quality of the bladder cancer care delivered.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 143K)
Save Article

Disease Site

Breast Disease

Disparities in medical care among commercially insured patients with newly diagnosed breast cancer : Opportunities for intervention (p NA)
Louise J. Short, Maxine D. Fisher, Peter M. Wahl, Monique B. Kelly, Grant D. Lawless, Sandra White, Nancy A. Rodriguez, Vincent J. Willey, Otis W. Brawley
Published Online: Oct 28 2009 5:05PM
DOI: 10.1002/cncr.24691

Disparities in medical care for newly diagnosed breast cancer were evident between African-American women and white women despite commercial health plan insurance coverage. Interventions that address the gaps identified are needed.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 171K)
Save Article

Head and Neck Disease

Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis (p NA)
Naomi Ramer, HaiShan Wu, Edmond Sabo, Yael Ramer, Patrick Emanuel, Lurmag Orta, David E. Burstein
Published Online: Oct 28 2009 5:06PM
DOI: 10.1002/cncr.24657

The present study is the first to examine and establish a correlation of the extent of p63 expression with prognosis of adenoid cystic carcinoma. It is performable on routinely fixed and processed tissue and represents a useful algorithmic method of quantifying p63 immunostaining.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 252K)
Save Article

Hematologic Malignancies

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome (p NA)
Ali Al Ameri, Charles Koller, Hagop Kantarjian, Farhad Ravandi, Srdan Verstovsek, Gautam Borthakur, Sherry Pierce, Gloria Mattiuzzi
Published Online: Oct 27 2009 2:18PM
DOI: 10.1002/cncr.24711

Acute pulmonary failure during remission induction therapy is a serious complication in patients with acute myeloid leukemia. Early acute pulmonary failure remains a serious complication of remission induction therapy, which is often complicated by subsequent other organ failure and death.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 140K)
Save Article

Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma (p NA)
Sikander Ailawadhi, Ahmed N. Abdelhalim, Lyudmyla Derby, Terry L. Mashtare, Kena C. Miller, Gregory E. Wilding, Ronald A. Alberico, Ronald Gottlieb, Donald L. Klippenstein, Kelvin Lee, Asher A. Chanan-Khan
Published Online: Oct 27 2009 2:20PM
DOI: 10.1002/cncr.24704

Magnetic resonance imaging of the bone marrow (BM-MRI) is a novel, noninvasive technique for assessing bone marrow involvement in multiple myeloma. The authors developed a semiquantitative BM-MRI staging system that correlates accurately with other conventional parameters of disease burden and can independently predict survival in patients with multiple myeloma at the time of initial diagnosis.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 298K)
Save Article

Discipline

Medical Oncology

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients (p NA)
Stephen Sonis, Nathaniel Treister, Sant Chawla, George Demetri, Frank Haluska
Published Online: Oct 27 2009 2:20PM
DOI: 10.1002/cncr.24696

Mammalian target of rapamycin inhibitor-associated stomatitis (mIAS) differed in behavior, appearance, and associated toxicities from mucositis induced by cytotoxic chemotherapy. The results from this study indicated that the similarity between mIAS and aphthous stomatitis may be the basis for an effective approach to its prevention and treatment.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 172K)
Save Article

Pediatric Oncology

The symptom interval in children and adolescents with soft tissue sarcomas (p NA)
Andrea Ferrari, Rosalba Miceli, Michela Casanova, Cristina Meazza, Francesca Favini, Roberto Luksch, Serena Catania, Marco Fiore, Carlo Morosi, Luigi Mariani
Published Online: Oct 27 2009 2:21PM
DOI: 10.1002/cncr.24695

This study investigated the effects of symptom interval in a large series of pediatric patients with soft tissue sarcomas, showing that symptom interval was associated with the patient's age and the size, site, and histological subtype of the tumor, and that longer intervals negatively influenced survival, in particular in the case of rhabdomyosarcoma.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 180K)
Save Article

Correspondence

The atypical Spitz tumor of uncertain biologic potential: A series of 67 patients from a single institution (p NA)
Carmelo Urso
Published Online: Oct 27 2009 2:21PM
DOI: 10.1002/cncr.24692

Abstract  |  References | Full Text:   HTML,   PDF (Size: 50K)
Save Article

Original Articles

Discipline

Clinical Trials

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma (p NA)
Tim Eisen, Uwe Trefzer, Anne Hamilton, Peter Hersey, Michael Millward, Robert D. Knight, Jarl U. Jungnelius, John Glaspy
Published Online: Oct 27 2009 2:21PM
DOI: 10.1002/cncr.24686

An international, multicenter, randomized, double-blind, controlled study assessed the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma. The study showed that treatment with lenalidomide (25 mg/d) has a manageable safety profile in patients with previously treated metastatic malignant melanoma, but provides no benefit in tumor response, time to progression, or overall survival in these patients.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 258K)
Save Article

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis (p NA)
Eric Jonasch, Paul Corn, Lance C. Pagliaro, Carla L. Warneke, Marcella M. Johnson, Pheroze Tamboli, Chaan Ng, Ana Aparicio, Robynne G. Ashe, John J. Wright, Nizar M. Tannir
Published Online: Oct 27 2009 2:21PM
DOI: 10.1002/cncr.24685

Untreated patients with metastatic renal cell carcinoma had similar outcomes when treated either with sorafenib alone or with sorafenib plus low-dose interferon. Activated protein kinase B may be a predictive biomarker of sorafenib resistance.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 148K)
Save Article

Outcomes Research

Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer (p NA)
Xin Shelley Wang, Qiuling Shi, Charles Lu, Ethan M. Basch, Valen E. Johnson, Tito R. Mendoza, Gary M. Mobley, Charles S. Cleeland
Published Online: Oct 22 2009 10:13AM
DOI: 10.1002/cncr.24703

Patient-reported symptom severity indicated increased risk for shorter survival in a group of patients with advanced nonsmall cell lung cancer who qualified for chemotherapy. These findings suggest that an individual patient's symptom severity scores, quickly obtainable in the clinic, might contribute clinically useful information for treatment planning for that patient.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 171K)
Save Article

Pediatric Oncology

Inflammatory myofibroblastic tumors in childhood : A report from the Italian Cooperative Group studies (p NA)
Rita Alaggio, Giovanni Cecchetto, Gianni Bisogno, Claudio Gambini, Maria Luisa Calabrò, Alessandro Inserra, Renata Boldrini, Gian Luca De Salvo, Emanuele S. G. d'Amore, Patrizia Dall'Igna
Published Online: Oct 22 2009 10:13AM
DOI: 10.1002/cncr.24684

Inflammatory myofibroblastic tumors (IMTs) are myofibroblastic lesions with unpredictable biologic behavior that occur in children and young adults. For this report, the authors investigated clinicopathologic features in a series of pediatric IMTs with the objective of identifying morphologic/immunohistochemical prognostic markers.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 428K)
Save Article

Correspondence

Racial disparities for uterine corpus tumors : Changes in clinical characteristics and treatment over time (p NA)
Jason D. Wright
Published Online: Oct 22 2009 10:12AM
DOI: 10.1002/cncr.24676

Abstract  |  References | Full Text:   HTML,   PDF (Size: 46K)
Save Article

Racial disparities for uterine corpus tumors : Changes in clinical characteristics and treatment over time (p NA)
William B. Grant
Published Online: Oct 22 2009 10:12AM
DOI: 10.1002/cncr.24689

Abstract  |  References | Full Text:   HTML,   PDF (Size: 49K)
Save Article

Original Articles

Discipline

Pediatric Oncology

Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (p NA)
Kristine R. Crews, Yinmei Zhou, Jennifer L. Pauley, Scott C. Howard, Sima Jeha, Mary V. Relling, Ching-Hon Pui
Published Online: Oct 15 2009 10:21AM
DOI: 10.1002/cncr.24681

Plasma methotrexate clearance in pediatric patients with newly diagnosed acute lymphoblastic leukemia was found to be significantly lower in patients who received concomitant allopurinol versus nonrecombinant or recombinant urate oxidase during high-dose methotrexate administration. A higher proportion of patients in the allopurinol group had elevated methotrexate plasma concentrations and experienced mucositis after methotrexate treatment compared with patients in the urate oxidase group.

Abstract  |  References | Full Text:   HTML,   PDF (Size: 143K)
Save Article

Cancer survivorship: Embracing the future North Bethesda, MD (p NA)

Published Online: Apr 22 2008 3:13PM
DOI: 10.1002/cncr.23599

Abstract | Full Text:   PDF (Size: 18K)
Save Article

click here
Latest News & Information
CNCR Impact Factor

Also of Interest
Patient Page
JournalCancer
twitter.com/JournalCancer
    follow Cancer on Twitter